IL157704A0 - 4,5-dihydro-1h-pyrazole derivatives having potent cbi-antagonistic activity - Google Patents
4,5-dihydro-1h-pyrazole derivatives having potent cbi-antagonistic activityInfo
- Publication number
- IL157704A0 IL157704A0 IL15770402A IL15770402A IL157704A0 IL 157704 A0 IL157704 A0 IL 157704A0 IL 15770402 A IL15770402 A IL 15770402A IL 15770402 A IL15770402 A IL 15770402A IL 157704 A0 IL157704 A0 IL 157704A0
- Authority
- IL
- Israel
- Prior art keywords
- dihydro
- antagonistic activity
- pyrazole derivatives
- cbi
- potent
- Prior art date
Links
- MCGBIXXDQFWVDW-UHFFFAOYSA-N 4,5-dihydro-1h-pyrazole Chemical class C1CC=NN1 MCGBIXXDQFWVDW-UHFFFAOYSA-N 0.000 title 1
- 230000000694 effects Effects 0.000 title 1
- 230000003389 potentiating effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Addiction (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Otolaryngology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01203849 | 2001-09-21 | ||
PCT/EP2002/010435 WO2003026648A1 (en) | 2001-09-21 | 2002-09-17 | 4,5-dihydro-1h-pyrazole derivatives having potent cb1-antagonistic activity |
Publications (1)
Publication Number | Publication Date |
---|---|
IL157704A0 true IL157704A0 (en) | 2004-03-28 |
Family
ID=8181042
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL15770402A IL157704A0 (en) | 2001-09-21 | 2002-09-17 | 4,5-dihydro-1h-pyrazole derivatives having potent cbi-antagonistic activity |
IL157704A IL157704A (en) | 2001-09-21 | 2003-09-02 | 4,5-dihydro-1h - pyrazole derivatives having potent cb1-antagonistic activity |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL157704A IL157704A (en) | 2001-09-21 | 2003-09-02 | 4,5-dihydro-1h - pyrazole derivatives having potent cb1-antagonistic activity |
Country Status (20)
Country | Link |
---|---|
US (2) | US6974810B2 (zh) |
EP (1) | EP1429762A1 (zh) |
JP (1) | JP4313672B2 (zh) |
KR (1) | KR100950430B1 (zh) |
CN (2) | CN1529595A (zh) |
AR (1) | AR036598A1 (zh) |
AU (1) | AU2002333853B2 (zh) |
BR (1) | BR0208253A (zh) |
CA (1) | CA2442245C (zh) |
HR (1) | HRP20030913A2 (zh) |
HU (1) | HUP0402113A3 (zh) |
IL (2) | IL157704A0 (zh) |
MX (1) | MXPA03009439A (zh) |
NO (1) | NO20041170L (zh) |
NZ (1) | NZ528280A (zh) |
PL (1) | PL367814A1 (zh) |
RU (1) | RU2286988C2 (zh) |
UA (1) | UA77441C2 (zh) |
WO (1) | WO2003026648A1 (zh) |
ZA (1) | ZA200307218B (zh) |
Families Citing this family (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003026648A1 (en) * | 2001-09-21 | 2003-04-03 | Solvay Pharmaceuticals B.V. | 4,5-dihydro-1h-pyrazole derivatives having potent cb1-antagonistic activity |
NZ534757A (en) | 2002-03-12 | 2006-07-28 | Merck & Co Inc | Substituted amides |
US7129239B2 (en) | 2002-10-28 | 2006-10-31 | Pfizer Inc. | Purine compounds and uses thereof |
US7247628B2 (en) | 2002-12-12 | 2007-07-24 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
US7329658B2 (en) | 2003-02-06 | 2008-02-12 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
US7176210B2 (en) | 2003-02-10 | 2007-02-13 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
US7141669B2 (en) | 2003-04-23 | 2006-11-28 | Pfizer Inc. | Cannabiniod receptor ligands and uses thereof |
US7145012B2 (en) | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
US7268133B2 (en) | 2003-04-23 | 2007-09-11 | Pfizer, Inc. Patent Department | Cannabinoid receptor ligands and uses thereof |
US7232823B2 (en) | 2003-06-09 | 2007-06-19 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
US20050239859A2 (en) * | 2003-09-03 | 2005-10-27 | Solvay Pharmaceuticals Gmbh | Novel medical uses of 4,5-dihydro-1h-pyrazole derivatives having cb1- antagonistic activity |
CN1956949A (zh) * | 2003-09-18 | 2007-05-02 | 默克公司 | 取代的磺酰胺 |
TW200528102A (en) * | 2003-10-24 | 2005-09-01 | Solvay Pharm Gmbh | Novel medical combination treatment of obesity involving 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity |
BRPI0415851A (pt) * | 2003-10-24 | 2007-01-02 | Solvay Pharm Gmbh | utilizações médicas de compostos que apresentam atividade antagonìstica de cb1 e tratamento de combinação envolvendo os referidos compostos |
US20050124660A1 (en) * | 2003-10-27 | 2005-06-09 | Jochen Antel | Novel medical uses of compounds showing CB1-antagonistic activity and combination treatment involving said compounds |
US20050143441A1 (en) * | 2003-10-27 | 2005-06-30 | Jochen Antel | Novel medical combination treatment of obesity involving 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity |
TW200522944A (en) | 2003-12-23 | 2005-07-16 | Lilly Co Eli | CB1 modulator compounds |
JP4693787B2 (ja) * | 2004-01-30 | 2011-06-01 | アボツト・ヘルスケア・プロダクツ・ベー・ブイ | Cb1拮抗活性を有する1,3,5−三置換4,5−ジヒドロ−1h−ピラゾール誘導体 |
US20080125403A1 (en) | 2004-04-02 | 2008-05-29 | Merck & Co., Inc. | Method of Treating Men with Metabolic and Anthropometric Disorders |
TW200602314A (en) | 2004-05-28 | 2006-01-16 | Tanabe Seiyaku Co | A novel pyrrolidine compound and a process for preparing the same |
CN101014605A (zh) | 2004-07-12 | 2007-08-08 | 卡地拉健康护理有限公司 | 用作大麻素受体调节物的三环吡唑衍生物 |
US20060025448A1 (en) | 2004-07-22 | 2006-02-02 | Cadila Healthcare Limited | Hair growth stimulators |
MX2007004889A (es) | 2004-10-25 | 2007-09-11 | Solvay Pharm Gmbh | Composiciones farmaceuticas que comprenden antagonistas del receptor cannabinoide cb1 y activadores de canales de potasio para el tratamiento de la diabetes mellitus tipo i, la obesidad y trastornos relacionados. |
ES2435790T3 (es) | 2004-12-03 | 2013-12-23 | Intervet International B.V. | Piperazinas sustituidas como antagonistas de CB1 |
US7923465B2 (en) | 2005-06-02 | 2011-04-12 | Glenmark Pharmaceuticals S.A. | Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation |
CA2613678A1 (en) | 2005-06-02 | 2006-12-07 | Glenmark Pharmaceuticals S.A. | Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation |
CA2613235A1 (en) | 2005-06-30 | 2007-01-11 | Prosidion Limited | Gpcr agonists |
EP1743890A1 (en) * | 2005-07-15 | 2007-01-17 | Laboratorios Del Dr. Esteve, S.A. | 4,5-Dihydro-1H-pyrazole derivatives, their preparation and use as medicaments |
CA2619480A1 (en) * | 2005-08-17 | 2007-02-22 | Solvay Pharmaceuticals Gmbh | Method of using potassium channel inhibiting compounds |
CA2637565A1 (en) * | 2006-01-18 | 2007-07-26 | Schering Corporation | Cannibinoid receptor modulators |
JP5561720B2 (ja) * | 2006-05-05 | 2014-07-30 | ジェンリン ディスカバリー | 肥満及び糖尿病を含む心臓血管障害を治療するために有用なカンナビノイド受容体アンタゴニスト/インバ−スアゴニスト |
US7964728B2 (en) | 2006-07-06 | 2011-06-21 | Solvay Pharmaceuticals B.V. | Azaindole derivatives with a combination of partial nicotinic acetyl-choline receptor agonism and dopamine reuptake inhibition |
AR062907A1 (es) * | 2006-09-22 | 2008-12-17 | Solvay Pharm Bv | Derivados de sulfonilpirazol y sulfonilpirazolincarboxamidina como antagonistas de 5-ht6 |
KR101434334B1 (ko) * | 2006-10-20 | 2014-08-28 | 아비에 비.브이. | 화학 물질의 마이셀 나노입자 |
US7923026B2 (en) | 2006-10-20 | 2011-04-12 | Solvay Pharmaceuticals B.V. | Embedded micellar nanoparticles |
BRPI0806312A2 (pt) | 2007-01-04 | 2011-09-06 | Prosidion Ltd | agonistas cgpr piperidina |
AR064735A1 (es) | 2007-01-04 | 2009-04-22 | Prosidion Ltd | Agonistas de gpcr y composicion farmaceutica en base al compuesto |
EP2377863A1 (en) | 2007-01-04 | 2011-10-19 | Prosidion Limited | Piperidine GPCR agonists |
PE20081849A1 (es) | 2007-01-04 | 2009-01-26 | Prosidion Ltd | Derivados de piperidin-4-il-propoxi-benzamida como agonistas de gpcr |
GB0700122D0 (en) | 2007-01-04 | 2007-02-14 | Prosidion Ltd | GPCR agonists |
WO2008130616A2 (en) * | 2007-04-19 | 2008-10-30 | Schering Corporation | Diaryl morpholines as cb1 modulators |
ES2393885T7 (es) | 2007-06-04 | 2014-01-30 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
CN101318931B (zh) * | 2007-06-04 | 2010-05-19 | 上海阳帆医药科技有限公司 | 二芳基取代吡唑衍生物、其制备方法和用途 |
CA2688208A1 (en) * | 2007-06-15 | 2008-12-18 | Solvay Pharmaceuticals B.V. | 4,5-dihydro-(1h)-pyrazole derivatives as cannabinoid cb1 receptor modulators |
US8410135B2 (en) | 2007-06-15 | 2013-04-02 | Solvay Pharmaceuticals B.V. | 4,5 dihydro-(1H)-pyrazole derivatives as cannabinoid CB1 receptor modulators |
EP2170847A2 (en) * | 2007-06-28 | 2010-04-07 | Intervet International BV | Substituted piperazines as cb1 antagonists |
KR20100051625A (ko) * | 2007-06-28 | 2010-05-17 | 인터벳 인터내셔널 비.브이. | Cb1 길항제로서의 치환된 피페라진 |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
GB0720389D0 (en) | 2007-10-18 | 2008-11-12 | Prosidion Ltd | G-Protein Coupled Receptor Agonists |
GB0720390D0 (en) | 2007-10-18 | 2007-11-28 | Prosidion Ltd | G-Protein coupled receptor agonists |
US7655685B2 (en) * | 2007-11-02 | 2010-02-02 | Jenrin Discovery, Inc. | Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes |
JP5551604B2 (ja) | 2007-11-30 | 2014-07-16 | オールトランツ インコーポレイティド | テトラヒドロカンナビノールのプロドラッグ、テトラヒドロカンナビノールのプロドラッグを含む組成物、及び同一のものを使用する方法 |
AR070898A1 (es) | 2008-03-18 | 2010-05-12 | Solvay Pharm Bv | Derivados de arilsulfonil pirazolin carboxamidina como antagonistas de 5-ht6 |
ES2522968T3 (es) | 2008-06-04 | 2014-11-19 | Synergy Pharmaceuticals Inc. | Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos |
AR071995A1 (es) * | 2008-06-16 | 2010-07-28 | Solvay Pharm Bv | Derivados de 3,4-diaril-4,5-dihidro-1h-pirazol-1-carboxamidina sustituidos con fluor que tienen actividad antagonista cb1, procesos de preparacion y composiciones farmaceuticas que los contienen |
AU2009270833B2 (en) | 2008-07-16 | 2015-02-19 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
TW201010981A (en) * | 2008-08-01 | 2010-03-16 | Solvay Pharm Bv | Synthesis of 3,4-diaryl-4,5-dihydro-(1H)-pyrazole-1-carboxamidine derivatives |
MX2011004258A (es) | 2008-10-22 | 2011-06-01 | Merck Sharp & Dohme | Derivados de bencimidazol ciclicos novedosos utiles como agentes anti-diabeticos. |
CA2741672A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
WO2010079241A1 (es) | 2009-01-12 | 2010-07-15 | Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion | Uso de antagonistas y/o agonistas inversos de los receptores cb1 para la preparación de medicamentos que incrementen la excitabilidad de las motoneuronas |
US8217038B2 (en) | 2009-10-07 | 2012-07-10 | Jenrin Discovery, Inc. | Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes |
AR079935A1 (es) | 2010-01-29 | 2012-02-29 | Abbott Healthcare Products Bv | Sintesis de derivados de pirazolin carboxamidina sustituida |
CA2786314A1 (en) | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
WO2011157827A1 (de) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
EP2640381A4 (en) | 2010-11-18 | 2014-05-21 | Jenrin Discovery | CANNABINOID RECEPTOR ANTAGONISTS / INVERSAGONISTS FOR THE TREATMENT OF METABOLISM DISEASES INCLUDING ADIPOSITAS AND DIABETES |
KR101668514B1 (ko) | 2011-02-25 | 2016-10-21 | 머크 샤프 앤드 돔 코포레이션 | 항당뇨병제로서 유용한 신규 시클릭 아자벤즈이미다졸 유도체 |
WO2012120057A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
US8846666B2 (en) | 2011-03-08 | 2014-09-30 | Sanofi | Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
US8809325B2 (en) | 2011-03-08 | 2014-08-19 | Sanofi | Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof |
US8962845B2 (en) * | 2011-09-30 | 2015-02-24 | National Health Research Institutes | Pyrazole compounds |
US8680131B2 (en) | 2012-07-25 | 2014-03-25 | Jenrin Discovery, Inc. | Cannabinoid receptor antagonists/inverse agonists useful for treating disease conditions, including metabolic disorders and cancers |
JP2015525782A (ja) | 2012-08-02 | 2015-09-07 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | 抗糖尿病性三環式化合物 |
JP6272626B2 (ja) | 2012-11-13 | 2018-01-31 | ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ | カンナビノイド受容体媒介性化合物 |
US11155521B2 (en) | 2012-11-13 | 2021-10-26 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Cannabinoid receptor mediating compounds |
RU2015140066A (ru) | 2013-02-22 | 2017-03-30 | Мерк Шарп И Доум Корп. | Противодиабетические бициклические соединения |
US9650375B2 (en) | 2013-03-14 | 2017-05-16 | Merck Sharp & Dohme Corp. | Indole derivatives useful as anti-diabetic agents |
CA2905435A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
JP2016514671A (ja) | 2013-03-15 | 2016-05-23 | シナジー ファーマシューティカルズ インコーポレイテッド | グアニル酸シクラーゼのアゴニストおよびその使用 |
US10011637B2 (en) | 2013-06-05 | 2018-07-03 | Synergy Pharmaceuticals, Inc. | Ultra-pure agonists of guanylate cyclase C, method of making and using same |
WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
EP3140288B1 (en) * | 2014-05-09 | 2023-01-25 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Pyrazole derivatives and their use as cannabinoid receptor mediators |
WO2018106518A1 (en) | 2016-12-06 | 2018-06-14 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
WO2022128050A1 (en) | 2020-12-14 | 2022-06-23 | Symrise Ag | Medicament for fighting inflammation and pain |
EP4341246A1 (en) * | 2021-05-17 | 2024-03-27 | The United States of America, as represented by The Secretary, Department of Health and Human Services | A facile and odor-free approach to convert sulfonyl urea derivatives to chalcogenide sulfonyl urea derivatives |
WO2023108036A1 (en) * | 2021-12-10 | 2023-06-15 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Cannabinoid receptor modulating compounds |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL158178B (nl) * | 1974-07-12 | 1978-10-16 | Philips Nv | Werkwijze ter bereiding van insekticide preparaten die een pyrazolinederivaat bevatten, aldus verkregen gevormde preparaten, en werkwijze ter bereiding van pyrazolinederivaten met insekticide werking. |
JPH03173887A (ja) * | 1989-03-27 | 1991-07-29 | Nissan Chem Ind Ltd | スルタムスルホンアミド及び除草剤 |
FR2692575B1 (fr) * | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
FR2789079B3 (fr) | 1999-02-01 | 2001-03-02 | Sanofi Synthelabo | Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant |
CA2401832C (en) * | 2000-03-23 | 2010-02-02 | Solvay Pharmaceuticals B.V. | 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity |
WO2003026648A1 (en) * | 2001-09-21 | 2003-04-03 | Solvay Pharmaceuticals B.V. | 4,5-dihydro-1h-pyrazole derivatives having potent cb1-antagonistic activity |
US20050124660A1 (en) * | 2003-10-27 | 2005-06-09 | Jochen Antel | Novel medical uses of compounds showing CB1-antagonistic activity and combination treatment involving said compounds |
US20050143441A1 (en) * | 2003-10-27 | 2005-06-30 | Jochen Antel | Novel medical combination treatment of obesity involving 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity |
-
2002
- 2002-09-17 WO PCT/EP2002/010435 patent/WO2003026648A1/en active IP Right Grant
- 2002-09-17 RU RU2003130268/04A patent/RU2286988C2/ru not_active IP Right Cessation
- 2002-09-17 AU AU2002333853A patent/AU2002333853B2/en not_active Ceased
- 2002-09-17 CA CA2442245A patent/CA2442245C/en not_active Expired - Fee Related
- 2002-09-17 CN CNA02808134XA patent/CN1529595A/zh active Pending
- 2002-09-17 HU HU0402113A patent/HUP0402113A3/hu unknown
- 2002-09-17 UA UA20040402981A patent/UA77441C2/uk unknown
- 2002-09-17 JP JP2003530285A patent/JP4313672B2/ja not_active Expired - Fee Related
- 2002-09-17 US US10/472,529 patent/US6974810B2/en not_active Expired - Fee Related
- 2002-09-17 CN CNA2007101543471A patent/CN101195604A/zh active Pending
- 2002-09-17 NZ NZ528280A patent/NZ528280A/en not_active IP Right Cessation
- 2002-09-17 KR KR1020047004076A patent/KR100950430B1/ko not_active IP Right Cessation
- 2002-09-17 PL PL02367814A patent/PL367814A1/xx not_active Application Discontinuation
- 2002-09-17 MX MXPA03009439A patent/MXPA03009439A/es active IP Right Grant
- 2002-09-17 BR BR0208253-5A patent/BR0208253A/pt not_active IP Right Cessation
- 2002-09-17 EP EP20020799409 patent/EP1429762A1/en not_active Withdrawn
- 2002-09-17 IL IL15770402A patent/IL157704A0/xx unknown
- 2002-09-18 AR ARP020103508A patent/AR036598A1/es unknown
-
2003
- 2003-09-02 IL IL157704A patent/IL157704A/en not_active IP Right Cessation
- 2003-09-15 ZA ZA200307218A patent/ZA200307218B/en unknown
- 2003-11-10 HR HR20030913A patent/HRP20030913A2/hr not_active Application Discontinuation
-
2004
- 2004-03-19 NO NO20041170A patent/NO20041170L/no not_active Application Discontinuation
-
2005
- 2005-11-03 US US11/265,090 patent/US7608718B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
MXPA03009439A (es) | 2004-02-12 |
EP1429762A1 (en) | 2004-06-23 |
IL157704A (en) | 2008-07-08 |
US7608718B2 (en) | 2009-10-27 |
NZ528280A (en) | 2005-11-25 |
RU2286988C2 (ru) | 2006-11-10 |
BR0208253A (pt) | 2004-04-13 |
AR036598A1 (es) | 2004-09-22 |
HUP0402113A2 (hu) | 2005-01-28 |
CN101195604A (zh) | 2008-06-11 |
CN1529595A (zh) | 2004-09-15 |
AU2002333853B2 (en) | 2006-07-13 |
HUP0402113A3 (en) | 2012-05-29 |
UA77441C2 (en) | 2006-12-15 |
JP2005503428A (ja) | 2005-02-03 |
WO2003026648A1 (en) | 2003-04-03 |
KR100950430B1 (ko) | 2010-04-02 |
KR20040035845A (ko) | 2004-04-29 |
US6974810B2 (en) | 2005-12-13 |
PL367814A1 (en) | 2005-03-07 |
RU2003130268A (ru) | 2005-01-27 |
CA2442245A1 (en) | 2003-04-03 |
CA2442245C (en) | 2010-03-30 |
ZA200307218B (en) | 2005-03-16 |
HRP20030913A2 (en) | 2004-06-30 |
US20040106800A1 (en) | 2004-06-03 |
NO20041170L (no) | 2004-06-21 |
JP4313672B2 (ja) | 2009-08-12 |
US20070259884A1 (en) | 2007-11-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL157704A0 (en) | 4,5-dihydro-1h-pyrazole derivatives having potent cbi-antagonistic activity | |
IL153508A0 (en) | 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity | |
IL160081A0 (en) | Novel 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity | |
IL160708A0 (en) | 1, 6-naphthyridine derivatives as antidiabetics | |
IL162377A0 (en) | 5,6-Diaryl-pyrazine-2-amide derivatives as cb1 antagonists | |
ZA200400926B (en) | Diamine derivatives. | |
HK1092461A1 (en) | Diamine derivatives | |
ZA200203252B (en) | Process for preparing 4"-substituted-9-deoxo-9A-AZA-9A-homoerythromycina derivatives. | |
IL161881A (en) | N,n'-substituted-1,3-diamino-2- hydroxypropane derivatives | |
HK1068608A1 (en) | 3-Substituted-4-pyrimidone derivatives | |
HUP0402171A3 (en) | Pyrazolopyrimidinone derivatives having pde7-inhibitory activity | |
MXPA03008216A (es) | Derivados de 3-fenilo. | |
HK1068607A1 (en) | Phenylalkyloxy-phenyl derivatives | |
HUP0303186A3 (en) | 4-aminobenzopyran derivatives | |
HUP0401949A3 (en) | 4-imidazolin-2-one derivatives | |
HUP0500026A3 (en) | N-heteroarylnicotinamide derivatives | |
IL162310A0 (en) | 3,4-Dihydro-1h-isoquinoloin-2-yl-derivatives | |
GB0130553D0 (en) | 1,4-Dihydro-1,4-diphenylpyridine derivitives | |
MXPA03008394A (es) | Derivados de biuretano. | |
IL162188A0 (en) | Process for the preparation of Ä1,4,5Ü-oxadiazepine derivatives | |
HK1066022A1 (en) | Use of 1,1,1,3,3-pentafluorobutan | |
EP1364954A4 (en) | Dicarba closo DODECARBORANDERIVATE | |
IL159965A0 (en) | Novel 2,4-diaminothiazole derivatives | |
PL370505A1 (en) | Substituted 1,5-diaminopentan-3-ol compounds | |
HUP0204401A3 (en) | Process for producing 2,6-dichlorophenol derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
KB | Patent renewed |